TevaISRAELinc

http://www.tevapharm.com/
http://hebrew.tevapharm.com/
Teva Pharmaceutical Industries Ltd. (Hebrew: טבע תעשיות פרמצבטיות בע"מ‎), NASDAQ: TEVA is an international pharmaceutical company headquartered in Petah Tikva, Israel. It specializes in generic and proprietary pharmaceuticals and active pharmaceutical ingredients. It is the largest generic drug manufacturer in the world[1] and one of the 15 largest pharmaceutical companies worldwide.[2] In 2008, sales totalled $11.08 billion, $13.9 billion in 2009, and in 2010 total sales rose to $16.1 billion, of which a major portion was in Europe and North America. Teva acquired its U.S. rival Ivax Corporation in January 2006, Barr in 2007 and Ratiopharm in 2010. Teva's facilities are located in Israel, North America, Europe, and Latin America. In 2010, it had 39,660 employees. In Israel, the number of workers rose 7.5% to 6,774.[3] In March 2010, Teva acquired German-based company Ratiopharm in a nearly $5 billion deal, significantly expanding its European coverage.[4][5][6]
As of February 2011, Teva is the tenth largest company by market capitalization on the Nasdaq just behind Gilead Sciences, and is a member of both the NASDAQ-100 and TA-25 Index (in which it represents 9.5% of the total Index value).
History

Teva's earliest predecessor was Salomon, Levin, and Elstein Ltd., a wholesale distributor based in Jerusalem that was founded in 1901. During the 1930s, new immigrants from Europe founded several pharmaceutical companies including Teva (literally "Nature" in Hebrew), Assia, and Zori. In 1951, Teva raised capital through the newly founded Tel-Aviv Stock Exchange.
In 1964, Assia and Zori merged and acquired a controlling interest in Teva. In 1976, these three companies merged into the modern Teva Pharmaceutical Industries Ltd. In 1980, Teva continued to follow its vision of becoming one of the world's biggest pharmaceutical companies by acquiring Ikapharm, then Israel's second largest drug manufacturer.[7]
Operations
In 1982, Teva was granted approval by the U.S. Food and Drug Administration (FDA) for its Kfar Sava manufacturing plant, an essential milestone for marketing pharmaceuticals in the USA.
In 2005, Teva opened a new, state-of-the-art pharmaceutical manufacturing plant in Har Hotzvim, a technology park in Jerusalem. The plant received FDA approval in early 2007. In 2010, Teva announced that it would be building its main distribution center for the Americas in Philadelphia, PA and was considering ope